-
Mashup Score: 23THE ONCOALERT NETWORK - 2 year(s) ago
Welcome to ​OncoAlert
Source: THE ONCOALERT NETWORKCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 2
AbstractBackground. Tumor angiogenesis is essential for solid tumor progression, invasion and metastasis. The aim of this study was to identify potential signal
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma - 2 year(s) ago
Glioblastoma (GBM) is notorious for its immunosuppressive tumor microenvironment (TME) and is refractory to immune checkpoint blockade (ICB). Here, we identify calmodulin-dependent kinase kinase 2 (CaMKK2) as a driver of ICB resistance. CaMKK2 is highly expressed in pro-tumor cells and is associated with worsened survival in patients with GBM. Host CaMKK2, specifically, reduces survival and…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Nociceptor neurons affect cancer immunosurveillance - 2 year(s) ago
Solid tumours are innervated by nerve fibres that arise from the autonomic and sensory peripheral nervous systems1–5. Whether the neo-innervation of tumours by pain-initiating sensory neurons affects cancer immunosurveillance remains unclear. Here we show that melanoma cells interact with nociceptor neurons, leading to increases in their neurite outgrowth, responsiveness to noxious ligands and…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Abstract. Trastuzumab deruxtecan is an HER 2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs patient-derived xenografts (PDX) models from human brain metastases and phase 0 and window of opportunity trials are of utmost importance.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Abstract. Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers, refractory to standard of care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Artificial intelligence can improve patients’ experience in decentralized clinical trials - 2 year(s) ago
Nature Medicine – Artificial intelligence can improve patients’ experience in decentralized clinical trials
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Blood monocyte-derived CD169+ macrophages contribute to antitumor immunity against glioblastoma - 2 year(s) ago
Infiltrating tumor-associated macrophages (TAM) are known to impede immunotherapy against glioblastoma (GBM), however, TAMs are heterogeneous, and there are no clear markers to distinguish immunosuppressive and potentially immune-activating populations. Here we identify a subset of CD169+ macrophages promoting an anti-tumoral microenvironment in GBM. Using single-cell transcriptome analysis, we…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
AbstractBackground. This systematic review provides updated insights, from the published literature in the past 5 years, based on the 2017 European Association
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2How I treat brain metastases of melanoma - 2 year(s) ago
Brain metastases are common in advanced melanoma and cause death in >50% of patients. Until recently, median survival was only ∼4 months. Improved systemic treatment including immune checkpoint inhibitors and combinations of BRAF/MEK inhibitors, however, has significantly improved intracranial tumor response and survival. In addition, advances in radiation therapy have also improved the…
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet
RT @OncoAlert: Dear Colleagues The @OncoAlert 🚨Newsletter comes out TOMORROW Thursday June 1st, 2023 Go to https://t.co/yzt83gqQkF To REGIS…